Cargando…
Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial
IMPORTANCE: Perioperative chemotherapy and surgery are a standard of care for operable gastroesophageal adenocarcinoma. Anti-HER2 therapy improves survival in patients with advanced HER2-positive disease. The safety and feasibility of adding lapatinib to perioperative chemotherapy should be assessed...
Autores principales: | Smyth, Elizabeth C., Rowley, Samuel, Cafferty, Fay H., Allum, William, Grabsch, Heike I., Stenning, Sally, Wotherspoon, Andrew, Alderson, Derek, Crosby, Tom, Mansoor, Was, Waters, Justin S., Neville-Webbe, Helen, Darby, Suzanne, Dent, Jo, Seymour, Matthew, Thompson, Joyce, Sothi, Sharmila, Blazeby, Jane, Langley, Ruth E., Cunningham, David |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587151/ https://www.ncbi.nlm.nih.gov/pubmed/31219517 http://dx.doi.org/10.1001/jamaoncol.2019.1179 |
Ejemplares similares
-
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial
por: Cunningham, David, et al.
Publicado: (2017) -
Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro‐oesophageal junction
por: Allum, W. H., et al.
Publicado: (2019) -
Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
por: Cheong, E. Von, et al.
Publicado: (2021) -
Src Mutation Induces Acquired Lapatinib Resistance in ERBB2-Amplified Human Gastroesophageal Adenocarcinoma Models
por: Hong, Yong Sang, et al.
Publicado: (2014) -
Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial
por: Alderson, Derek, et al.
Publicado: (2017)